Enterprise Value
879.6M
Cash
553M
Avg Qtr Burn
-49.77M
Short % of Float
20.97%
Insider Ownership
2.73%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Azenosertib (ZN-c3) (oral inhibitor of WEE1) w/ chemo Details Ovarian cancer, Cancer, Platinum-resistant ovarian cancer | Phase 3 Initiation | |
Azenosertib (ZN-c3) (oral inhibitor of WEE1) Details Uterine disease, Cancer | Phase 2 Data readout | |
Azenosertib (ZN-c3) comb w/ encorafenib and cetuximab Details Cancer, Metastatic colorectal cancer | Phase 1/2 Data readout | |
ZN-d5 (oral selective inhibitor of B-cell lymphoma 2 (BCL-2)) Details Cancer, relapsed or refractory light chain amyloidosis, Post-stroke recovery | Phase 1/2 Data readout | |
ZN-d5 (oral selective inhibitor of B-cell lymphoma 2 (BCL-2)) Details Non-Hodgkin lymphoma, Acute myeloid leukemia, Cancer | Phase 1b Data readout | |
ZN-c5: Oral SERD (Monotherapy) Details Breast cancer, Cancer | Failed Discontinued | |
ZN-c5 (Oral SERD) +Verzenio® (abemaciclib) Details Breast cancer, Cancer | Failed Discontinued |